Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
Authors
Keywords
Personalized, Peptide receptor radionuclide therapy, <sup>177</sup>Lu-octreotate, Dosimetry, Neuroendocrine tumours
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-11-30
DOI
10.1007/s00259-018-4209-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
- (2017) Anna Sundlöv et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study
- (2017) Michela Del Prete et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Dose Mapping After Endoradiotherapy with177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days
- (2017) Heribert Hänscheid et al. JOURNAL OF NUCLEAR MEDICINE
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- High risk of myelodysplastic syndrome and acute myeloid leukemia after177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy
- (2016) Bertrand Brieau et al. ENDOCRINE-RELATED CANCER
- Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
- (2014) Samer Ezziddin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study
- (2014) D. Wild et al. JOURNAL OF NUCLEAR MEDICINE
- Hematological Toxicity of Combined177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up
- (2014) Murali Kesavan et al. NEUROENDOCRINOLOGY
- Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [177Lu-DOTA0,Tyr3]Octreotate
- (2013) E. I. van Vliet et al. JOURNAL OF NUCLEAR MEDICINE
- Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors
- (2012) Phillip G. Claringbold et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177Lu-DOTA-Octreotate Treatment
- (2012) M. Sandstrom et al. JOURNAL OF NUCLEAR MEDICINE
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
- (2011) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Evaluation of 177Lu-DOTA-sst2 Antagonist Versus 177Lu-DOTA-sst2 Agonist Binding in Human Cancers In Vitro
- (2011) R. Cescato et al. JOURNAL OF NUCLEAR MEDICINE
- Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Tyr3]Octreotate
- (2011) S. Khan et al. JOURNAL OF NUCLEAR MEDICINE
- Quantitative 177 Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system
- (2011) Jean-Mathieu Beauregard et al. CANCER IMAGING
- 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
- (2010) Daniel Hubble et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate
- (2009) Mattias Sandström et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
- (2008) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- (2008) Dik J. Kwekkeboom et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now